基于美国FAERS数据库的地拉罗司不良事件信号挖掘与分析

doi:10.19803/j.1672-8629.20240031

中国药物警戒 ›› 2024, Vol. 21 ›› Issue (8): 931-935.
DOI: 10.19803/j.1672-8629.20240031

基于美国FAERS数据库的地拉罗司不良事件信号挖掘与分析

钟红¹, 陈红², 张玄羿¹, 邓慧远¹, 罗相林³, 万杰¹, 孔文强^1,*

¹自贡市第一人民医院药剂科,四川自贡 643000;
²自贡市贡井区中医医院药剂科,四川自贡 643000;
³自贡市第一人民医院信息科,四川自贡 643000

收稿日期:2024-01-01 出版日期:2024-08-15 发布日期:2024-08-21
通讯作者: ^*孔文强,男,硕士,主管药师,临床药学。E-mail: WQkongpharmacist@outlook.com
作者简介:钟红,女,硕士,主管药师,临床药学。
基金资助:
四川省自贡市卫健委项目（22yb063）

Detection and analysis of signals of adverse events induced by deferasirox based on FAERS

ZHONG Hong¹, CHEN Hong², ZHANG Xuanyi¹, DENG Huiyuan¹, LUO Xianglin³, WAN Jie¹, KONG Wenqiang^1,*

¹Department of Pharmacy, the First People’s Hospital of Zigong City, Zigong Sichuan 643000 China;
²Department of Pharmacy, Gongjing TCM Hospital of Zigong City, Zigong Sichuan 643000 China;
³Department of Information, the First People’s Hospital of Zigong City, Zigong Sichuan 643000 China

Received:2024-01-01 Online:2024-08-15 Published:2024-08-21

摘要/Abstract

摘要： 目的挖掘地拉罗司不良事件（AE）风险信号,为临床安全用药提供参考。方法提取美国食品药品监督管理局（FDA）不良事件报告系统（FAERS）数据库中地拉罗司从2005年11月1日上市至2023年9月30日的AE报告,按《监管活动医学词典》（MedDRA）系统-器官分类（SOC）和首选术语（PT）进行分类,采用报告比值法（ROR）和信息成分法（IC）,挖掘并分析可疑风险信号。结果共检索到以地拉罗司为首要怀疑的AE报告19 657份,男女比例为1.04∶1,患者年龄集中在18~85岁（7 948份,40.43%）。检测到地拉罗司AE信号870个,累及20个SOC。报告数前20位的PT中,说明书未记载的可疑阳性信号有4个,主要集中在感染及侵染类疾病（2个）及全身性疾病及给药部位各种反应（2个）。结论临床应用地拉罗司时,除关注药品说明书收录的不良反应外,还应密切关注其致感染、脑血管意外、便秘、过敏性心肌炎等风险,保障患者用药安全。

关键词: 地拉罗司, FDA不良事件报告系统, 不良事件, 信号挖掘, 报告比值法, 信息成分法, 感染及侵染类疾病, 全身性疾病, 给药部位各种反应

Abstract: Objective To provide reference for clinical safe medication by exploring adverse event reports of deferasirox. Methods The adverse event (AE) reports of deferasirox collected between November 2005 and September 2023 were retrieved from FAERS database, and classified according to the system organ class (SOC) and preferred term (PT). Suspicious risk signals were mined and analyzed using the reporting odds ratio (ROR) and information component (IC) method. Results A total of 19 657 AEs related to deferasirox as the primary suspect were reported. The male-to-female ratio was 1.04 : 1 and the age mainly ranged from 18 to 85 years old (7 948 cases, 40.43%). A total of 870 AE signals were detected, involving 20 SOC. Among the top 20 PTs of reports, 4 positive signals were not mentioned in drug instructions, including infections, infestations (2 signals), general disorders and administration site conditions (2 signals). Conclusion In clinical use of deferasirox, clinicians should be alert not only to adverse reactions, but to the risk of infection, cerebrovascular accidents, constipation and hypersensitivity myocarditis so as to ensure the safety of medication for patients.

Key words: deferasirox, FDA adverse event reporting system(FAERS), adverse event, signal detection, ROR, IC, infections, infestations, general disorders, administration site conditions

中图分类号:

R973
R994.11

钟红, 陈红, 张玄羿, 邓慧远, 罗相林, 万杰, 孔文强. 基于美国FAERS数据库的地拉罗司不良事件信号挖掘与分析[J]. 中国药物警戒, 2024, 21(8): 931-935.

ZHONG Hong, CHEN Hong, ZHANG Xuanyi, DENG Huiyuan, LUO Xianglin, WAN Jie, KONG Wenqiang. Detection and analysis of signals of adverse events induced by deferasirox based on FAERS[J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 931-935.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://zgywjj.magtechjournal.com/CN/10.19803/j.1672-8629.20240031

https://zgywjj.magtechjournal.com/CN/Y2024/V21/I8/931

参考文献

[1] KATTAMIS A, KWIATKOWSKI JL, AYDINOK Y.Thalassaemia[J]. Lancet, 2022, 399(10343): 2310-2324.
[2] KILLICK SB, WISEMAN DH, QUEK L, et al.British Society for Haematology guidelines for the diagnosis and evaluation of prognosis of adult myelodysplastic syndromes[J]. Br J Haematol, 2021, 194(2): 282-293.
[3] Red Blood Cell Disease (Anemia) Group, Chinese Society of Hematology, Chinese Medical Association. Guidelines for the diagnosis and management of aplastic anemia in China (2022)[J]. Chin J Hematol(中华血液学杂志) , 2022, 43(11): 881-888.
[4] HSU CC, SENUSSI NH, FERTRIN KY, et al.Iron overload disorders[J]. Hepatol Commun, 2022, 6(8): 1842-1854.
[5] FDA. EXJADETM(deferasirox) tablets, for oral suspension Initial U.S. Approval-2005[EB/OL].(2020-07-23)[2023-03-21]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021882s033lbl.pdf.
[6] ENTEZARI S, HAGHI SM, NOROUZKHANI N, et al.Iron chelators in treatment of iron overload[J]. J Toxicol, 2022, 2022: 4911205.
[7] CAPPELLIN MD, BEJAOU M, AGAOGLU L, et al.Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years’follow-up[J]. Blood, 2011, 118(4): 884-893.
[8] CAPPELLIN MD, PORTER J, EL-BESHLAW A, et al.Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias[J]. Haematologica, 2010, 95(4): 557-566.
[9] TOWERMAN AS, GUILLIAMS KP, GUERRIERO R, et al.Hyperammonemia and acute liver failure associated with deferasirox in two adolescents with sickle cell disease[J]. Br J Haematol, 2023, 201(4): e30-e33.
[10] RAMASWAMI A, ROSEN DJ, CHU J, et al.Fulminant liver failure in a child with β-thalassemia on deferasirox: a case report[J]. J Pediatr Hematol Oncol, 2017, 39(3): 235-237.
[11] SUBEESH V, MAHESWARI E, SINGH H, et al.Novel adverse events of iloperidone: a disproportionality analysis in US Food and Drug Administration Adverse Event Reporting System (FAERS) database[J]. Curr Drug Saf, 2019,14(1): 21-26.
[12] HU Y, GONG J, ZHANG L, et al.Colitis following the use of immune checkpoint inhibitors: a real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system[J]. Int Immunopharmacol, 2020, 84: 106601.
[13] WU L, INGLE T, LIU Z, et al.Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA[J]. BMC Bioinformatics, 2019, 20(Suppl 2): 97.
[14] BATE A, EVANS SJ.Quantitative signal detection using spontaneous ADR reporting[J]. Pharmacoepidemiol Drug Saf, 2009, 18(6): 427-436.
[15] KHALEEL MA, KHAN AH, GHADZI SMS, et al.A standardized dataset of a spontaneous adverse event reporting system[J]. Healthcare (Basel), 2022,10(3): 420.
[16] SCOGLIO M, CAPPELLINI MD, D’ANGELO E, et al. Kidney tubular damage secondary to deferasirox: systematic literature review[J]. Children (Basel), 2021, 8(12): 1104.
[17] BABU T, PANACHIYIL GM, SEBASTIAN J, et al.Effectiveness and tolerability of twice daily dosing of deferasirox in unresponsive and intolerant transfusion-dependent beta-thalassemia patients: a narrative review[J]. Indian J Pharmacol, 2020, 52(6): 514-519.
[18] FANG QT, WU XR, ZHANG MR, et al.Signal detection and analysis of the adverse events induced by abemaciclib based on open FDA[J]. Clin J Hosp Pharm(中国医院药学杂志) , 2022, 42(7): 726-731.
[19] YEW CT, TALAULIKAR GS, FALK MC, et al.Acute interstitial nephritis secondary to deferasirox causing acute renal injury needing short-term dialysis[J]. Nephrology (Carlton), 2010,15(3): 377.
[20] DUBOURG L, LAURAIN C, RANCHIN B, et al.Deferasirox-induced renal impairment in children: an increasing concern for pediatricians[J]. Pediatr Nephrol, 2012, 27(11): 2115-2122.
[21] YUI JC, GEARA A, SAYANI F.Deferasirox-associated Fanconi syndrome in adult patients with transfusional iron overload[J]. Vox Sang, 2021, 116(7): 793-797.
[22] KATTAMIS A.Renal function abnormalities and deferasirox[J]. Lancet Child Adolesc Health, 2019, 3(1): 2-3.
[23] BIRD ST, SWAIN RS, TIAN F, et al.Effects of deferasirox dose and decreasing serum ferritin concentrations on kidney function in paediatric patients: an analysis of clinical laboratory data from pooled clinical studies[J]. Lancet Child Adolesc Health, 2019, 3(1): 15-22.
[24] TAHER A, CAPPELLINI MD, VICHINSKY E, et al.Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload[J]. Br J Haematol, 2009, 147(5): 752-759.
[25] NIRENBERG A, BUSH AP, DAVIS A, et al.Neutropenia: state of the knowledge part I[J]. Oncol Nurs Forum, 2006, 33(6): 1193-1201.
[26] FRUSTACI A, VERARDO R, LABBADIA G, et al.Hypersensitivity myocarditis following deferasirox administration[J]. Circ Cardiovasc Imaging, 2022, 15(2): e013702.

基于美国FAERS数据库的地拉罗司不良事件信号挖掘与分析

Detection and analysis of signals of adverse events induced by deferasirox based on FAERS

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	赵俊, 董丽, 王洋, 梁瑜, 杨雪, 李恩泽. 艾司洛尔不良反应/事件报告分析[J]. 中国药物警戒, 2024, 21(8): 925-930.
[2]	时贯宏, 王淇, 孙昊, 陈雁杰, 储紫雁, 蒋傲, 汤在祥, 刘静芳. 基于美国FAERS数据库抗抑郁药物与胎儿及新生儿的不良事件信号分析[J]. 中国药物警戒, 2024, 21(6): 687-692.
[3]	武一,何金阳,王晓剑,周效竹,刘冉佳,郭明星,赵莹,代文迪,崔向丽. 基于美国VAERS数据库的肝、肾移植受者接种新型冠状病毒疫苗不良事件分析[J]. 中国药物警戒, 2024, 21(5): 572-579.
[4]	张健, 张伶俐, 李歆. 424例替雷利珠单抗致免疫相关不良事件分析[J]. 中国药物警戒, 2024, 21(4): 435-439.
[5]	韩丽, 陈力, 陈乾, 肖洪涛. 基于美国FAERS数据库索磷布韦/维帕他韦和来迪派韦/索磷布韦不良反应信号分析[J]. 中国药物警戒, 2024, 21(4): 440-446.
[6]	游晓炎, 郑盈盈, 王宪英. 基于FAERS数据库的英夫利西单抗不良事件信号挖掘分析[J]. 中国药物警戒, 2024, 21(3): 335-340.
[7]	吴汀溪, 赵志刚, 石延枫, 张杨, 张伊楠, 朱斌. 基于FAERS数据库的秋水仙碱相关神经毒性风险分析[J]. 中国药物警戒, 2024, 21(3): 341-345.
[8]	王珊, 谢波, 刘慧敏, 李志浩. 基于FAERS数据库对塞来昔布不良事件信号的分析[J]. 中国药物警戒, 2024, 21(2): 190-194.
[9]	沈艳杰, 吴奕卿. 临床试验期间不良事件管理的实践与思考[J]. 中国药物警戒, 2023, 20(9): 982-986.
[10]	何雄, 马俊龙, 阳国平. 基于FAERS对靶向HER2抗体偶联药品不良反应/事件的分析[J]. 中国药物警戒, 2023, 20(8): 915-920.
[11]	潘喆敏, 徐圣, 郑轶, 陈晨鑫, 刘永梅, 张朋朋, 叶小飞, 贺佳. 上市后不良反应评价中似然比检验方法的比较[J]. 中国药物警戒, 2023, 20(6): 655-660.
[12]	赵稳华, 舒鹤, 倪晨明, 郭晋敏. 基于FAERS数据库的氨吡啶缓释片不良反应信号挖掘分析[J]. 中国药物警戒, 2023, 20(6): 684-690.
[13]	陈亚昆, 门鹏, 王攀. 基于FAERS数据库的4种磷酸二酯酶5抑制剂安全性分析[J]. 中国药物警戒, 2023, 20(6): 691-696.
[14]	梁士兵, 余泽宇, 孔令垚, 晏利姣, 韩梅, 吴嘉瑞, 刘兆兰, 刘建平. 文献计量法在中药药物警戒领域中的应用价值及展望[J]. 中国药物警戒, 2023, 20(5): 591-594.
[15]	资文瑞, 杨秋月, 苏俊, 谢江安. 我国上市人乳头瘤病毒疫苗接种及安全性研究[J]. 中国药物警戒, 2023, 20(3): 311-316.